













































































(LTRA) １例，LABA+LTRA ２例，LABA+ 徐放



















かったが ( 前：1.59±0.113 L, 後：1.62±0.113 
L, p=0.4148)，末梢気道の閉塞所見を反映する







DPI: 吸入ステロイド薬変更前（DPI 製剤使用時）， HFA-
CIC: 吸入ステロイド薬変更12週後（シクレソニド使用










DPI 製剤：FP ８例／ BUD ２例（１日400μg を使用）
併用薬 ： 吸入長時間作動型β2刺激薬 (LABA) １例、
ロイコトリエン受容体拮抗薬 (LTRA) １例、
LABA+LTRA ２例、LABA+ 徐放性テオフィリ
ン (Th) ２例、LABA+LT+Th ３例、なし１例
17加藤，他：喘息におけるシクレソニドの効果
0.605±0.144 L/sec, p=0.4434） お よ び Vdot50
（ 前：1.468±0.183 L/sec, 後：1.796±0.271 L/
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The effect of ciclesonide on the airflow obstruction in the small airways
and asthma-related quality of life in patients with asthma.
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1) Department of Respiratory Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Japan
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ABSTRACT  The small airways have recently attracted close attention as an important site of 
airway inflammation. The present study was undertaken to analyze the changes in the quality 
of life (QOL) and lung function following treatment with ciclesonide (HFA-CIC), with the goal 
of evaluating the usefulness of small-particle-sized inhaled corticosteroid (ICS) in the treatment 
of small airway lesions. The study was conducted on 10 patients with moderately persistent 
asthma who gave informed consent for participation in this study (5 males and 5 females with 
a mean age of 72 years). In these patients pulmonary function testing revealed persistent 
obstruction of the small airways even after treatment with another ICS (DPI preparation) at 
moderate or higher dose levels. After 4 weeks of observation, the ICS was switched to HFA-
CIC that delivers a small particle sized aerosol. The latter was administered for 12 weeks. A 
QOL questionnaire survey was administered and pulmonary function testing was performed 
immediately before and 12 weeks after the drug switch. The results obtained after the switch 
were then compared with those documented prior to the switch. Inhalational treatment with 
HFA-CIC was associated with a significant improvement in the QOL. Although the forced 
expiratory volume in one second (FEV1) remained unchanged, a significant improvement of 
the Vdot50 was observed after inhalational therapy with HFA-CIC. No adverse reactions were 
apparent during the HFA-CIC treatment. Thus, the use of a small-particle-sized ICS (MDI 
preparation) resulted in an alleviation of small airway obstruction and an improvement in the 
QOL. If an ICS suitable for individual cases can be used, better responses to treatment may be 
obtained.
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